B Acute Lymphoblastic Leukemia: Clinical Trials

10 trials for B Acute Lymphoblastic Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 active not recruiting, 2 completed, 1 recruiting, 1 unknown. 10 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Active not recruiting 6, Completed 2, Recruiting 1, Unknown 1
Phase 22Completed 1, Recruiting 1

Follow B Acute Lymphoblastic Leukemia: new trials by email Literature Review of B Acute Lymphoblastic Leukemia trials Research Report on B Acute Lymphoblastic Leukemia

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission
Autologous Anti-CD19 CAR-expressing T Lymphocytes, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia
Phase 1Active not recruitingCity of Hope Medical Center182023-04-262026-10-08
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ), Nivolumab starting at day -1 - B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Phase 1 / Phase 2RecruitingAssistance Publique - Hôpitaux de Paris262023-03-152024-05-29
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 1Active not recruitingOHSU Knight Cancer Institute202022-09-022026-05-06
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia
Phase 1Active not recruitingCity of Hope Medical Center242022-03-172026-05-28
TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)
PBLTT52CAR19 - B Acute Lymphoblastic Leukemia
Phase 1CompletedGreat Ormond Street Hospital for Children NHS Foundation Trust92020-08-122024-03-07
Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive
Phase 1Active not recruitingStanford University332017-10-202026-06-30
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive
Phase 1Active not recruitingStanford University562017-09-012025-11-18
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
AUTO3 (CD19/22 CAR T cells - B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Phase 1 / Phase 2CompletedAutolus Limited232017-06-262021-02-01
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
prophylactic 4SCAR19 cells - B Acute Lymphoblastic Leukemia
Phase 1UnknownThe First People's Hospital of Yunnan302015-03-012016-11-18
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Laboratory Biomarker Analysis - B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia
Phase 1Active not recruitingCity of Hope Medical Center712014-10-162026-08-05

Narrower conditions

Burkitt Lymphoma (10)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Neoplasm, Residual (2)  ·  Leukemia, B-Cell (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Recurrence (1)

Broader conditions

DNA Virus Infections (10)  ·  Epstein-Barr Virus Infections (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Herpesviridae Infections (10)  ·  Immune System Diseases (10)  ·  Immunoproliferative Disorders (10)  ·  Infections (10)  ·  Lymphatic Diseases (10)  ·  Lymphoma (10)  ·  Lymphoma, B-Cell (10)  ·  Lymphoma, Non-Hodgkin (10)  ·  Lymphoproliferative Disorders (10)  ·  Neoplasms (10)  ·  Neoplasms by Histologic Type (10)  ·  Tumor Virus Infections (10)

Interventions

Cyclophosphamide (4)  ·  Biopsy (2)  ·  Immunotherapy, Adoptive (2)  ·  Methotrexate (2)  ·  Prednisone (2)  ·  Specimen Handling (2)  ·  deltacortene (2)  ·  fludarabine phosphate (2)  ·  merphos (2)  ·  prednylidene (2)  ·  venetoclax (2)  ·  CT-P10 (1)  ·  Cytarabine (1)  ·  Dasatinib (1)  ·  Daunorubicin (1)

Sponsors

City of Hope Medical Center (3)  ·  Stanford University (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Autolus Limited (1)  ·  Great Ormond Street Hospital for Children NHS Foundation Trust (1)  ·  OHSU Knight Cancer Institute (1)  ·  The First People's Hospital of Yunnan (1)

Countries

United States (6)  ·  United Kingdom (2)  ·  China (1)  ·  France (1)

Top investigators

Ibrahim Aldoss (2)  ·  Ajay Vora, Prof, MD (1)  ·  Crystal Mackall (1)  ·  Huang Jianzhang, Doctor (1)  ·  Ibrahim T Aldoss (1)  ·  Jessica T Leonard (1)  ·  Kanchan Rao, PhD, MD (1)  ·  Lori Muffly, MD, MS (1)  ·  Paul Veys, PhD, MD (1)  ·  Waseem Qasim, Prof (1)

Results publications

PMID 42341322, PMID 32772769, PMID 32929049, PMID 34312556, PMID 34515338, PMID 34889384, PMID 36288281, PMID 36821767, PMID 38968138, PMID 41671463

NIH funding

P30CA033572 (2), 2016 (1)